{"id":"eritrityl-tetranitrate","rwe":[{"pmid":"26647149","year":"2015","title":"Identifying Raman and Infrared Vibrational Motions of Erythritol Tetranitrate.","finding":"","journal":"Applied spectroscopy","studyType":"Clinical Study"},{"pmid":"19406636","year":"2009","title":"NO donors. Part 18: Bioactive metabolites of GTN and PETN--synthesis and vasorelaxant properties.","finding":"","journal":"Bioorganic & medicinal chemistry letters","studyType":"Clinical Study"},{"pmid":"10024078","year":"1999","title":"Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs.","finding":"","journal":"Metabolism: clinical and experimental","studyType":"Clinical Study"},{"pmid":"9918783","year":"1998","title":"Pentaerithrityl tetranitrate and its phase I metabolites are potent activators of cellular cyclic GMP accumulation.","finding":"","journal":"Biochemical and biophysical research communications","studyType":"Clinical Study"},{"pmid":"10180293","year":"1998","title":"Erythrityl tetranitrate; drug efficacy study implementation; revocation of exemption; opportunity for a hearing--FDA. Notice.","finding":"","journal":"Federal register","studyType":"Clinical Study"}],"tags":[{"label":"Vasodilators Organic Nitrates","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C01DA13","category":"atc"},{"label":"Active","category":"status"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"unknown","safety":{"drugInteractions":[{"url":"/drug/sildenafil","drug":"sildenafil","action":"Avoid combination","effect":"May interact with Erythrityl Tetranitrate, Sildenafil Citrate","source":"DrugCentral","drugSlug":"sildenafil"},{"url":"/drug/vardenafil","drug":"vardenafil","action":"Avoid combination","effect":"May interact with Erythrityl Tetranitrate, Vardenafil","source":"DrugCentral","drugSlug":"vardenafil"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"tetranitrin","offLabel":[],"synonyms":["erythrityl tetranitrate","eritrityl tetranitrate","nitroerythrite","nitroerythrol","tetranitrin"],"timeline":[],"approvals":[],"brandName":"Tetranitrin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Vasodilators Organic Nitrates","explanation":"Think of it like a valve in a pipe: when the valve is open, the pipe can flow more easily. Nitric oxide is like a chemical that opens the valve, allowing blood to flow more freely and reducing pressure in the blood vessels.","oneSentence":"Tetranitrin works by releasing nitric oxide, which relaxes smooth muscle and increases blood flow.","technicalDetail":"Tetranitrin is a prodrug that undergoes metabolic conversion to release nitric oxide, which then activates guanylyl cyclase and increases cyclic guanosine monophosphate (cGMP) levels, leading to smooth muscle relaxation and vasodilation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Erythritol_tetranitrate","title":"Erythritol tetranitrate","extract":"Erythritol tetranitrate (ETN) is an explosive compound chemically similar to PETN, though it is thought to be slightly more sensitive to friction and impact.","wiki_history":"== History ==\nETN was discovered by John Stenhouse in 1849 by nitrating erythritol he recently discovered. He described its explosive properties but suggested an incorrect formula due to atomic weights not yet being accurately determined.\n\nIts vasodilator properties have been researched since 1895.\n\nDuPont researched the explosive after the war, getting a patent in 1928, but it was never commercialized due to the difficulty of erythritol synthesis. Only due to genetically-engineered yeasts in the 1990s did it become possible for the carbohydrate to become widely available."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1047","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=eritrityl tetranitrate","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Erythritol_tetranitrate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:06:33.805080","biosimilars":[],"competitors":[{"drugName":"glyceryl trinitrate","drugSlug":"glyceryl-trinitrate","fdaApproval":"1981-05-28","relationship":"same-class"},{"drugName":"isosorbide dinitrate","drugSlug":"isosorbide-dinitrate","fdaApproval":"1968-01-16","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"isosorbide mononitrate","drugSlug":"isosorbide-mononitrate","fdaApproval":"1991-12-30","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"eritrityl tetranitrate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glyceryl-trinitrate","brandName":"glyceryl trinitrate","genericName":"glyceryl trinitrate","approvalYear":"1981","relationship":"same-class"},{"drugId":"isosorbide-dinitrate","brandName":"isosorbide dinitrate","genericName":"isosorbide dinitrate","approvalYear":"1968","relationship":"same-class"},{"drugId":"isosorbide-mononitrate","brandName":"isosorbide mononitrate","genericName":"isosorbide mononitrate","approvalYear":"1991","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000147067","NDDF":"000685","UNII":"35X333P19D","VUID":"4018764","CHEBI":"CHEBI:60072","VANDF":"4018764","INN_ID":"1448","RXNORM":"4040","UMLSCUI":"C0014758","ChEMBL_ID":"CHEMBL2107583","KEGG_DRUG":"D04051","DRUGBANK_ID":"DB01613","PUBCHEM_CID":"5284553","SNOMEDCT_US":"398960003","MESH_DESCRIPTOR_UI":"D004897"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":34,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"C01DA13","allCodes":["C01DA13","C01DA63"]},"biosimilarFilings":[],"recentPublications":[{"date":"2015 Dec","pmid":"26647149","title":"Identifying Raman and Infrared Vibrational Motions of Erythritol Tetranitrate.","journal":"Applied spectroscopy"},{"date":"2009 Jun 1","pmid":"19406636","title":"NO donors. Part 18: Bioactive metabolites of GTN and PETN--synthesis and vasorelaxant properties.","journal":"Bioorganic & medicinal chemistry letters"},{"date":"1999 Feb","pmid":"10024078","title":"Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs.","journal":"Metabolism: clinical and experimental"},{"date":"1998 Dec 30","pmid":"9918783","title":"Pentaerithrityl tetranitrate and its phase I metabolites are potent activators of cellular cyclic GMP accumulation.","journal":"Biochemical and biophysical research communications"},{"date":"1998 Jun 23","pmid":"10180293","title":"Erythrityl tetranitrate; drug efficacy study implementation; revocation of exemption; opportunity for a hearing--FDA. Notice.","journal":"Federal register"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Tetranitrin, also known as eritrityl tetranitrate, is a small molecule vasodilator in the organic nitrates class. Its exact target is unknown, but it is believed to work by releasing nitric oxide, which relaxes smooth muscle and increases blood flow. Tetranitrin's commercial status and approved indications are unclear, and it is not known whether it is FDA-approved or off-patent. Further research is needed to fully understand its pharmacology and clinical applications. As a result, key safety considerations and dosing information are not well established.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}